FOR IMMEDIATE RELEASE
September 21, 2023

IC Surgical, Inc. Announces Breakthrough Clinical Study Published Reporting Improved Outcomes in Breast Cancer Patients Undergoing Post-Mastectomy Breast Reconstruction with Novel Interi^® System

Results demonstrate a statistically significant reduction in seroma and other complications.

Grand Rapids, MI –September 20, 2023– IC Surgical, Inc., an innovator in surgical technologies, announces the independent publication of a groundbreaking clinical study showcasing the success of the Interi™ System in breast reconstruction. This pivotal research, "Reduction in Seroma and Other Complications with a Novel Internal Negative Pressure System in Breast Reconstruction", offers compelling evidence of the Interi System's effectiveness in reducing complications compared to traditional drains. The study, recently published in Plastic and Reconstructive Surgery Global Open in September 2023, demonstrates the potential for the Interi System to significantly improve outcomes for breast cancer patients undergoing post-mastectomy breast reconstruction.

In the study, author Dr. Robert Paul evaluated the safety and efficacy of the Interi System compared to standard drains in 200 prepectoral breast reconstructions patients, in two well-matched cohorts. The results demonstrate a substantial reduction in seroma and other complications when the Interi System is used. The study included 170 Interi System and 166 standard drain surgical placements and demonstrated a statistically significant reduction in four key outcomes measurements: seroma formation, skin/ mastectomy flap revision, any complication, and number of days on therapy.

Dr. Bradley Bengtson, founder of the Bengtson Center for Aesthetics and Plastic Surgery, and Medical Director of IC Surgical, expressed excitement about the significance of Dr Paul's data. "These results reinforce our belief in the Interi™ System's ability to not only improve surgical outcomes in procedures that typically carry a 20-30% complication rate, but transform recovery experiences in patients undergoing breast reconstruction and other major open procedures. This technology is significantly reducing complications, improving patient satisfaction, and ultimately reducing the total cost of care.”

The author notes that the observed reductions in mastectomy/skin flap revisions and seroma are indicative of improved internal wound healing, even in high-risk patients, and that the Interi System has the potential to significantly improve patient outcomes.

The paper can be accessed on the Plastic and Reconstructive Surgery Global Open website.

About IC Surgical
IC Surgical is a commercial stage medical technologies company focused on innovative concepts to address complex issues in surgery. The company is the developer and marketer of the Interi System, a transformative new technology, designed to provide internal control of surgically-damaged tissue by delivering continuous consistent suction pressure throughout internal tissue planes – in a simple yet elegant way. This innovative solution represents a novel approach to long-standing issues in post-surgical management, offering not only the potential for enhanced outcomes but also a more comfortable recovery experience.

For Media Inquiries, Please Contact:
Ron Novotny
Email: RonNovotny@icsurgical.com
www.icsurgical.com